Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-Labeled Humanized MN-14 and PBSCR in Advanced Ovarian Cancer
NCT00004177Phase 2Completed
- Sponsor
- Garden State Cancer Center
- Start
- Aug 1999
- Primary completion
- May 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 labetuzumab in ovarian cancer, sponsored by Garden State Cancer Center. Primary endpoints: Maximum Tolerated Dose at 12 weeks and Normal organ and tumor dosimetry. Started Aug 1999; status: completed.
02
Drugs
yttrium-90 labetuzumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00004177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004177.